erous enzymes that are now known to be regulated by S-nitrosylation. Accumulating evidence suggests that many disease states are associated with aberrant protein S-nitrosylation. Dr. Stamler's group also identified the enzyme responsible for bioactivation of nitroglycerin, the ability of red blood cells to dilate blood vessels and a role for nitric oxide in the human respiratory cycle.
Duke University and Johns Hopkins University has awarded Cordex an exclusive worldwide license to a portfolio of compounds targeting the redox-NO imbalance as a new therapeutic modality in the management of patients with heart failure disease. Dr. Stamler is a scientific consultant to Cordex.
About Cordex Pharma, Inc.
Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex is developing a portfolio of therapeutic and diagnostic products, two of which are in advanced stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia early in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 safety clinical trial in heart failure patients early in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.
This press release contains Page: 1 2 3 4 5 Related biology technology :1
. Axikin Pharmaceuticals Spins out of Actimis2
. Asbestos, Pharmaceutical Liability, Construction Defects, Nanotech: Covered by Targeted CLE Teleconferences3
. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine4
. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 20155
. Cracking the Code: Exclusive Conference to Reveal Secrets of Chinese Pharmaceutical Industry6
. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer7
. Cumberland Pharmaceuticals Appoints Lee Product Director8
. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program9
. ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross10
. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference11
. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing